{"id":"NCT04355117","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients","officialTitle":"A Multicenter, Open-label Trial to Evaluate the Safety of TEV-48125 When Subcutaneously Self-administered in Migraine Patients at the Trial Site and at Home","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-17","primaryCompletion":"2020-11-11","completion":"2020-11-11","firstPosted":"2020-04-21","resultsPosted":"2021-10-28","lastUpdate":"2021-10-28"},"enrollment":71,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.","otherNames":[]}],"arms":[{"label":"Treatment: TEV-48125","type":"EXPERIMENTAL"}],"summary":"This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home. Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses. The first dose will be self-administered at the trial site under the supervision of the investigator and the second dose will be self-administered at home.","primaryOutcome":{"measure":"Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)","timeFrame":"[1] Baseline (Day 1) to Day 28, [2] Visit 3 (Day 29) up to end of treatment (Day 57)","effectByArm":[{"arm":"Self-administration at Trial Site","deltaMin":18,"sd":null},{"arm":"Self-administration at Home","deltaMin":26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Injection site erythema","Injection site induration","Injection site pain","Injection site pruritus","Injection site haemorrhage"]}}